Phase 3 Readout
SMMT: Phase 3 Topline: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrex
December 31, 2026 · ak112. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- Summit Therapeutics Inc. (SMMT)
- Drug
- ak112
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrex
- Drug
- ak112
- Indication
- Non-Squamous Non-small Cell Lung Cancer